MicroRNA 204 mediated negative regulation of the IGF2R promotes breast cancer progression and is a potential mechanism driving breast cancer disparity
暂无分享,去创建一个
David P Turner | Lourdes M. Nogueira | K. Helke | E. Garrett-Mayer | V. Findlay | D. Turner | D. Watson | Victoria J. Findlay | Laurel E. Black | J. Fox | Clare E Burton
[1] Runsheng Li,et al. A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells , 2015, Oncotarget.
[2] T. Ma,et al. miR‐204 functions as a tumor suppressor by regulating SIX1 in NSCLC , 2014, FEBS letters.
[3] Lei Ma,et al. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. , 2014, International journal of clinical and experimental pathology.
[4] N. Selvamurugan,et al. Regulation of Breast Cancer and Bone Metastasis by MicroRNAs , 2013, Disease markers.
[5] H. Selby,et al. Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models , 2013, Clinical Cancer Research.
[6] Lourdes M. Nogueira,et al. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer , 2013, Breast Cancer Research.
[7] Han Liu,et al. PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis , 2013, Science Signaling.
[8] Jueheng Wu,et al. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. , 2013, Cancer research.
[9] A. Pertsemlidis,et al. Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization , 2012, PloS one.
[10] R. Berkowitz,et al. Dysregulation of microRNA‐204 mediates migration and invasion of endometrial cancer by regulating FOXC1 , 2012, International journal of cancer.
[11] D. Epstein,et al. Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells. , 2011, Investigative ophthalmology & visual science.
[12] E. Paquet,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[13] Jun Yu,et al. A microRNA contribution to aberrant Ras activation in gastric cancer. , 2011, American journal of translational research.
[14] Douglas Hanahan,et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.
[15] Dawn L Hershman,et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.
[16] David P Turner,et al. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. , 2008, Cancer research.
[17] Manfred Kunz,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.
[18] Adrian V. Lee,et al. Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS)-1 and IRS-2 , 2007, Cell cycle.
[19] Adrian V. Lee,et al. Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail , 2007, Molecular and Cellular Biology.
[20] D. Macphee,et al. A Dose-Dependent Decrease in the Fraction of Cases Harboring M6P/IGF2R Mutations in Hepatocellular Carcinomas from the Atomic Bomb Survivors , 2006, Radiation research.
[21] T. Mak,et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.
[22] C. Benz,et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.
[23] Brandy M Heckman,et al. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. , 2006, Molecular endocrinology.
[24] H. Kuniyasu,et al. Alterations of the M6p/Igf2 receptor gene in hepatocellular carcinomas induced by N‐nitrosodiethylamine and a choline‐deficient L‐amino acid–defined diet in rats , 2004, Molecular carcinogenesis.
[25] C. Roberts,et al. The insulin-like growth factor system and cancer. , 2003, Cancer letters.
[26] Zhihong Chen,et al. Decreased expression of the mannose 6- phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells , 2002, BMC Cancer.
[27] Robert B Boxer,et al. A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[29] A. Costantino,et al. Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.
[30] M. Ellis,et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene , 1998, Breast Cancer Research and Treatment.
[31] A. Leaf,et al. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Walsh,et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. , 1997, British Journal of Cancer.
[33] E. Diamandis,et al. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. , 1996, British Journal of Cancer.
[34] R. Bentley,et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. , 1996, Oncogene.
[35] D. Rifkin,et al. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Czech,et al. Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. , 1985, The Journal of biological chemistry.
[37] M. Anscher,et al. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[38] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.